Sign in

    Samir Devani

    Research Analyst at Rx Securities

    Dr. Samir Devani is Managing Director at Rx Securities, specializing as a medical technology and pan-European biotechnology analyst with over two decades of experience. He covers notable companies including PharmaMar and Orexo and is recognized for his extensive advisory work and successful secondary market fundraising and IPOs in the European healthcare sector, though specific performance metrics or rankings are not publicly available. Dr. Devani began his career at JP Morgan, followed by roles at Numis Securities, Altium Capital, and as a founding partner of Code Securities, which later became Nomura Code Securities before joining Rx Securities in April 2016. Holding a degree in Pharmacy from London University and a PhD in pharmaceutical technology from King’s College London, he is widely respected for his expertise and leadership in healthcare investment banking.

    Samir Devani's questions to Valneva (VALN) leadership

    Samir Devani's questions to Valneva (VALN) leadership • Q1 2025

    Question

    Samir Devani from Rx Securities asked for confirmation on the fulfillment of the DUKORAL order for Mayotte. He also inquired about how to model the La Réunion IXCHIQ order for the upcoming quarters and whether recent adverse events in the elderly have prompted a reconsideration of the IXCHIQ dose for the pediatric study.

    Answer

    CEO Thomas Lingelbach and CFO Peter Buhler confirmed the DUKORAL order for Mayotte was fulfilled in Q1. Buhler added that the majority of the La Réunion IXCHIQ order was supplied in Q2. Regarding the pediatric dose, Lingelbach stated that they have not seen any unexpected safety profiles in younger populations and, at this point in time, have not reconsidered the dose for the planned Phase III infant study.

    Ask Fintool Equity Research AI

    Samir Devani's questions to Valneva (VALN) leadership • Q1 2025

    Question

    Samir Devani from Rx Securities asked for confirmation on the fulfillment of the DUKORAL order for Mayotte, how to model the IXCHIQ order for La Réunion, and whether recent adverse events in the elderly have led to a reconsideration of the dose for upcoming pediatric studies.

    Answer

    CEO Thomas Lingelbach confirmed the DUKORAL order for Mayotte was fulfilled in Q1. CFO Peter Buhler added that the majority of the La Réunion IXCHIQ order was supplied in Q2. Regarding the pediatric dose, Mr. Lingelbach stated that they have not reconsidered the dose at this time, as no unexpected safety signals have been observed in younger adults or adolescents.

    Ask Fintool Equity Research AI

    Samir Devani's questions to BioXcel Therapeutics (BTAI) leadership

    Samir Devani's questions to BioXcel Therapeutics (BTAI) leadership • Q3 2024

    Question

    Asked for confirmation on a change to the TRANQUILITY In-Care trial design, progress on partnering BXCL701, and details about the recent inventory write-down.

    Answer

    The at-home pilot cohort has been removed from the TRANQUILITY In-Care trial protocol. The partnering process for BXCL701 is ongoing. Following the inventory write-down, the company has sufficient product for the next few years.

    Ask Fintool Equity Research AI

    Samir Devani's questions to BioXcel Therapeutics (BTAI) leadership • Q3 2024

    Question

    Samir Devani from Rx Securities asked for confirmation on whether the TRANQUILITY In-Care trial still includes an at-home cohort, the progress on partnering BXCL701, and details on the recent inventory write-down.

    Answer

    Executive Vincent O'Neill confirmed that the 20-patient at-home pilot cohort was removed from the TRANQUILITY In-Care protocol following internal discussions. He also noted the partnering process for BXCL701 is ongoing but taking longer than anticipated. Executive Richard Steinhart added that after the recent noncash write-down, the company has sufficient inventory for the next couple of years.

    Ask Fintool Equity Research AI

    Samir Devani's questions to BioXcel Therapeutics (BTAI) leadership • Q1 2024

    Question

    Samir Devani sought confirmation that the 12-month safety study for TRANQUILITY In-Care is required before an sNDA filing and asked what the trigger is for initiating that trial.

    Answer

    Executive Vincent O'Neill confirmed that the long-term safety data is needed to support an sNDA submission and that they are discussing protocol details with the FDA. Executive Vimal Mehta clarified that the trigger for initiation is securing financing for the trial through data readout, adding that technical readiness preparations are already underway.

    Ask Fintool Equity Research AI